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mary, unilateral, elective total hip arthroplasty were randomized to 220 mg oral dabigatran
once daily, starting with a 110 mg half-dose, 1e4 hours after surgery, or subcutaneous enox-
aparin 40 mg once daily, starting the evening before surgery. Each group received a placebo
of the other study drug. The primary efficacy outcome was the composite of total venous
thromboembolism (VTE) and all-cause mortality. Secondary outcome measures were compos-
ite of major VTE and VTE-related mortality during the treatment period. The major safety
outcome was incidence of bleeding events.
Results: Of the 179 Indian patients randomized, 91 received oral dabigatran and 88 received
subcutaneous enoxaparin for 28e35 days. Total VTE and all-cause mortality occurred in
18.7% of patients in the dabigatran group and 13.7% in the enoxaparin group [odds
ratio Z 1.4 (95% confidence interval 0.6, 3.5)]. Major VTE and VTE-related mortality was
numerically lower in the dabigatran group (7.9%) compared with the enoxaparin group
(9.9%). Safety outcomes were comparable between both groups.
Conclusion: Dabigatran is an effective oral alternative to enoxaparin for thromboprophylaxis
as demonstrated by the RE-NOVATE II study global results. Data analyzed in Indian patients
indicate comparable effects of dabigatran etexilate for major efficacy and safety outcomes.
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reserved.1. Introduction
Total hip arthroplasty (THA) is an effective surgical inter-
vention for relieving pain and improving physical function in
osteoarthritis.1 Severe osteoarthritis and hip fragility frac-
tures due to osteoporosis are the main conditions requiring
THA. In India, osteoarthritis, secondary to avascular ne-
crosis and/or trauma to the hip joint as well as inflamma-
tory arthritis are the commonest indications for THA. It is
one of the most successful orthopedic procedures. The
demand for THA is expected to continually increase.2
Venous thromboembolism (VTE) is a common complica-
tion of surgical procedures. Reduction in fibrinolytic activ-
ity postsurgery and the occurrence of Virchow’s triad
(venous stasis, abnormal coagulation, and intimal damage)
due to general anesthesia leads to intravascular coagula-
tion.3 VTEs can present as deep vein thrombosis (DVT) or
pulmonary embolism (PE). The reported incidence range of
DVT in Indian patients after THA without thromboprophy-
laxis is 40e70%, proximal DVT is 10e20%, clinical DVT is
1e3%, nonfatal symptomatic pulmonary thromboembolism
is 1e2%, and fatal pulmonary thromboembolism is 0.1e1%.4
The incidence of DVT after THA without prophylaxis in Asian
patients was similar to those reported in patients from
western countries.5
Thromboprophylactic treatment is recommended for
up to 35 days postsurgery as symptomatic VTEs can
develop up to 3 months following surgery or asymptomatic
DVTs can become symptomatic in this duration.6 Low
molecular weight heparins (LMWH) or vitamin K antago-
nists such as phenprocoumon, acenocoumarol, and
warfarin are traditionally used for thromboprophylaxis.
The LMWH are parenteral agents, and their administration
is a challenge as most patients are discharged within a
week postsurgery. Routine anticoagulant monitoring and
dose adjustments are required for warfarin and other
vitamin K antagonists.7lhotra R, et al., Thromboprophyl
ble-dummy, randomized RE-NOVThe need for parenteral administration and routine
monitoring required with the traditional thromboprophy-
lactic agents hampers compliance and recovery in patients
with THA. The recently available oral anticoagulant dabi-
gatran etexilate provides thromboprophylaxis when
administered postoperatively and improves compliance
postdischarge. Dabigatran etexilate is a small molecule
prodrug of dabigatran, a competitive reversible, direct
thrombin inhibitor. A Phase III (RE-NOVATE) study8 has
demonstrated the noninferiority of dabigatran 150 mg or
220 mg once daily (started after surgery) to subcutaneous
LMWH enoxaparin 40 mg once daily (started before surgery)
for the prevention of VTE and all-cause mortality after THA.
Bleeding and adverse event (AE) rates with dabigatran were
low and similar to enoxaparin. Dabigatran 220 mg once
daily (starting with half a dose on the day of surgery) is now
approved in more than 75 countries for thromboprophylaxis
in patients undergoing THA. The efficacy and safety of
28e35 days of oral dabigatran thromboprophylaxis was
further evaluated in a more diverse population from 19
countries, including India (RE-NOVATE II).9 The aim of this
article is to discuss data from the RE-NOVATE II study spe-
cific to the Indian patients who represent Asian ethnicity,
and identify any trends in relation with the global findings
(RE-NOVATE II)9 published previously.2. Methods2.1. Study participants
Patients were recruited from March 2008 until May 2009.
Patients of either sex, aged 18 years and above, undergoing
primary unilateral elective total hip replacement surgery
were included in the study. Exclusion criteria for the RE-
NOVATE II9 study were similar to those reported in previous
studies8,10,11 and aimed to ensure the patient safety.axis with dabigatran after total hip arthroplasty in Indian patients:
ATE II study, Asian Journal of Surgery (2015), http://dx.doi.org/
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and hemorrhagic stroke; (2) excessive risk of bleeding as
perceived by the investigator; (3) major surgery or trauma
within 3 months of enrollment; (4) recent unstable car-
diovascular disease; (5) active liver disease or alanine
transaminase more than three times the upper limit of
normal range; and (6) known severe renal insufficiency
(with creatinine clearance < 30 mL/min) were excluded.
Patients treated with anticoagulants, clopidogrel, ticlopi-
dine, abciximab, aspirin > 162.5 mg/d, or nonsteroidal
anti-inflammatory drugs within 7 days prior to hip
replacement surgery or with anticipated need for these
agents during the period were excluded from the trial.
Patients who had spinal or epidural anesthesia for which
more than three attempts (sticks) at placement were
made, or in whom the placement was traumatic, were
excluded from the study. Patients likely to need quinidine
and verapamil during the study were excluded.
The study was approved by the respective Institutional
Ethics Committees and conducted according to the Decla-
ration of Helsinki. All patients signed informed consent
form before participating in the study.
2.2. Study site
The study was conducted in 14 centers across India at the
following hospitals: (1) All India Institute of Medical Sci-
ences, Delhi; (2) Sushrut Hospital, Nagpur; (3) Yashoda
Hospital, Secunderabad; (4) St. John’s Medical College &
Hospital, Bangalore; (5) Kasturba Medical College, Man-
galore; (6) Center for Knee Surgery, Baroda; (7) Siddhi
Nursing Home, Mumbai; (8) Krishna Institute of Medical
Sciences, Hyderabad; (9) Shalby Hospitals Pvt. Ltd.,
Ahmedabad; (10) Vadodara Institute for Reconstructive
Orthopedic Care, Vadodara; (11) M.S. Ramaiah Memorial
Hospital, Bangalore; Jehangir Hospital, Pune; and (12)
Fortis Hospital, Mohali.
2.3. Study design and treatment
This was a prospective, double-blind, double-dummy study.
The patient, the investigator, their staff, and clinical
monitors were unaware of the treatment assigned.
Patients were randomized into two groups for up to
3 days prior to surgery. A 40 mg subcutaneous injection of
enoxaparin (enoxaparin arm) or a matching placebo (in the
dabigatran arm) was started the evening before surgery. In
the dabigatran arm, half a dose (one capsule) of dabigatran
was administered orally 1e4 hours postsurgery. A full dose
of dabigatran (2  110 mg capsules) was given the morning
after surgery and onwards as once-daily dosing. In the
enoxaparin arm, subcutaneous treatment was continued
thereafter every 24 hours. All patients received a matching
placebo of the other study drug (double-dummy) respec-
tively. Treatment was continued for 28e35 days (including
the day of surgery) or until a bilateral venography was
performed to detect any asymptomatic DVT. If a confirmed
VTE (DVT or PE) occurred before treatment completion, the
treatment was continued up to a maximum of 42 days.
Safety was assessed during the treatment period and the
two follow-up visits (at 63  7 days and 91  7 days).Please cite this article in press as: Malhotra R, et al., Thromboprophyla
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The primary efficacy outcome was measured using bilateral
venography and was the composite of total VTE (i.e.,
asymptomatic DVT detected with bilateral venography,
symptomatic DVT confirmed with venography, venous
compression ultrasound, or by autopsy, and PE confirmed
with perfusion scintigraphy, chest X-ray, pulmonary angi-
ography, spiral computed tomography or autopsy) and all-
cause mortality during the treatment period. All-cause
mortality was defined as the time from the first adminis-
tration of the study drug until 3 days after the last admin-
istration. The important secondary outcome measures were
composite of major VTE (defined as proximal DVT and/or
PE) and VTE-related mortality during the treatment period.
Other secondary outcomes during the treatment period
were occurrence of total DVT (asymptomatic or symptom-
atic), proximal DVT (asymptomatic or symptomatic),
symptomatic DVT, PE, and death. The secondary outcome
measure during the follow-up period was the composite of
total VTE and all-cause mortality.
The major safety outcome measures were the in-
cidences of bleeding events (categorized as major, clini-
cally relevant, or minor bleeding events), volume of blood
loss, requirement for blood transfusions, occurrence of AEs,
discontinuation of study treatment due to AEs, and abnor-
malities in laboratory safety parameters with particular
focus on liver function tests. Definitions of bleeding events
are as reported previously.8,10,11
A central and independent adjudication committee, who
were blinded to the treatment allocation, objectively
reviewed and interpreted all efficacy and safety parame-
ters. The results of this review were used for analysis.
2.5. Randomization procedure
Randomization was stratified by center and prepared in
blocks of four with the lowest number allocated sequen-
tially. Treatment group assignment was concealed from the
investigators, their staff, and the clinical monitors.
2.6. Analysis
The data on Indian population is presented in terms of
descriptive statistics as numbers, percentages, two-sided
95% confidence interval (CI), median (range), mean, and
standard deviation.
3. Results
3.1. Baseline data
Of the 195 patients enrolled in India, 179 patients were
randomized to receive either oral dabigatran (N Z 91) or
enoxaparin (N Z 88). Of the 179 patients, 168 (93.9%)
received the study medications as per the study protocol.
Ninety patients were treated and operated in the dabiga-
tran group while the enoxaparin group consisted of 87 such
patients. A total of 75 patients and 73 patients were
evaluable for primary efficacy outcomes in the dabigatranxis with dabigatran after total hip arthroplasty in Indian patients:
ATE II study, Asian Journal of Surgery (2015), http://dx.doi.org/
Table 2 Surgical characteristics.
Characteristics Dabigatranb Enoxaparinb
Treated and operated (N ) 90 87
General anesthesia 6 (6.7%) 5 (5.7%)
Regional anesthesia 82 (91.1%) 82 (94.3%)
General and regional
anesthesia
2 (2.2%) 0 (0.0%)
Duration of surgery (min) 90
(30e330)
95
(30e240)
Time from surgery to first oral
or s.c. dose (h)
2.8
(1.3e21.4)
12.6
(e37 to 9.5)
Duration of oral treatmenta (d) 32
(3e45)
31
(2e43)
Duration of s.c. treatment (d) 32
(1e45)
31
(1e43)
s.c. Z subcutaneous.
a Enoxaparin group received placebo capsules.
b Data expressed as number of patients (percentage) or me-
dian (range).
Table 3 Efficacy outcomes.
Characteristics Dabigatrana Enoxaparina
Total VTE and all-cause
mortality 95% CI
14/75 (18.7%)
[9.8, 27.5]
10/73 (13.7%)
[5.8, 21.6]
Asymptomatic DVT 14 (18.7%) 9 (12.3%)
Symptomatic DVT 0 (0%) 0 (0%)
Nonfatal PE 0 (0%) 0 (0%)
Death associated with VTE 0 (0%) 0 (0%)
Death not associated
with VTE
0 (0%) 1 (1.4%)
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mographic characteristics of the two randomized treatment
groups are well balanced as described in Table 1. The sur-
gical characteristics are described in Table 2.
3.2. Efficacy outcomes
Total VTE and all-cause mortality (primary endpoint)
occurred in 18.7% (95% CI, 9.8%, 27.5%) of patients in the
dabigatran group and 13.7% (95% CI, 5.8%, 21.6%) of pa-
tients in the enoxaparin group in Indian patients, resulting
in an odds ratio over enoxaparin of 1.4 (95% CI, 0.6, 3.5).
Asymptomatic DVT was the main contributor to the primary
endpoint. Major VTE and VTE-related mortality (secondary
endpoint) were low in the dabigatran group (7.9%)
compared with the enoxaparin group (9.9%) as shown in
Table 3. The percentage of patients with proximal DVTs
during the treatment period was numerically lower in the
dabigatran group than the enoxaparin group while the
reverse was seen in cases of distal DVTs. No incidence of PE
occurred in the Indian patients.
3.3. Safety outcomes
A major bleeding event occurred in one patient (1.1%) in
the dabigatran group. It was not fatal and did not require
treatment cessation or reoperation. No major bleeding
events occurred in the enoxaparin-treated patients. The
number of major or clinically relevant nonmajor bleeding
events was low in both the treatment groups (Table 4).
The summary of AEs observed in the study is presented
in Table 5. Patients in the enoxaparin group had a higher
percentage of AEs and serious adverse events (SAEs) than
those in the dabigatran group. In patients with SAEs, four
patients (4.5%) had prolonged hospitalization in the enox-
aparin group compared with one patient (1.1%) in the
dabigatran group. The investigator evaluated that the drug-
related AEs were higher in the enoxaparin group compared
with the dabigatran group. Patients in the dabigatran group
had no incidences of wound hemorrhage while the enox-
aparin group had one such occurrence. The number of AEs
leading to treatment discontinuation was similar in both
treatment groups. Alanine transaminase elevation at any
point of time after baseline was reported to be three times
above the upper limit of normal range in 3.5% of patients in
the enoxaparin group compared with 1.1% in the dabigatran
group. The event of total bilirubin elevation was reportedTable 1 Demographic characteristics of treated patients.
Characteristics Dabigatrana Enoxaparina
Treated patients (N ) 91 88
Age (yr) 47.7  14 50.9  14.4
Female 35 (38.5%) 32 (36.4%)
Weight (kg) 61.8  12.7 61.7  13.1
Body mass index (kg/m2) 23.6  4.2 23.5  5
Creatinine clearance (mL/min) 98.2  34.4 94.2  29.9
a Data expressed as mean  standard deviation or number
(percentage) of patients.
Please cite this article in press as: Malhotra R, et al., Thromboprophyl
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within the dabigatran group.
4. Discussion
DVT and PE are considered two of the most significant
complications after THA, warranting thromboprophylaxis.
The peak incidence of clinical DVT appears to occur
5e10 days after hip arthroplasty and continues to be
diagnosed up to 6 weeks or 8 weeks after hospital
discharge.12 The American College of Chest PhysiciansMajor VTE and VTE-related
mortality 95% CI
6/76 (7.9%)
[1.8, 14.0]
7/71 (9.9%)
[2.9, 16.8]
Total DVT 14/75 (18.7%) 9/72 (12.5%)
Proximal DVT 6/76 (7.9%) 7/71 (9.9%)
Distal DVT 8/75 (10.7%) 2/73 (2.7%)
Symptomatic DVT 0 (0%) 0 (0%)
Symptomatic nonfatal PE 0 (0%) 0 (0%)
Death 0/90 (0%) 1/87 (1%)
Total VTE and all-cause
mortality during follow-up
0/90 (0%) 1/87 (1%)
CI Z confidence interval; DVT Z deep vein thrombosis;
PE Z pulmonary embolism; VTE Z venous thromboembolism.
a Data presented as number of patients who had an event/
total number of patients (percentage), (95% CI).
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Table 4 Safety outcomes (bleeding events).
Characteristics India
Dabigatran Enoxaparin
Treated patients (N ) 91 88
Major bleeding events (no. of
patients, %) (95% CI)
1 (1.1%)a
(0e6%)
0 (0%)
(0e4.1%)
Fatal 0 0
In a critical organb 0 0
>20 g/L fall in hemoglobinc 1 0
Leading to  2units transfusionc 1 0
Warranting treatment cessation 0 0
Leading to reoperation 0 0
Major or clinically relevant
nonmajor bleeding events
2 (2.2%) 1 (1.1%)
CI Z confidence interval.
a Occurred before administration of dabigatran.
b Symptomatic retroperitoneal, intracranial, intraocular or
intraspinal bleeding.
c In excess of what the investigator expected.
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28e35 days postsurgery. With LMWH, extended thrombo-
prophylaxis is significantly more effective in preventing VTE
in orthopedic surgery patients than the recommended
practice of 10 days.13 Extended thromboprophylaxis with
enoxaparin for 4 weeks [after THA/total knee arthroplasty
(TKA)] has shown to significantly reduce the incidence of
VTE significantly (0.5% vs. 3.27%) compared with short-termTable 5 Other safety outcomes.
Characteristics Dabigatrana Enoxaparina
Number of patients (N ) 91 88
No. (%) with any adverse event 53 (58.2%) 54 (61.4%)
Serious adverse events 4 (4.4%) 8 (9.1%)
Fatal 0 (0%) 1 (1.1%)
Immediately life threatening 1 (1.1%) 1 (1.1%)
Disability/incapacity 0 (0%) 0 (0%)
Requiring hospitalization 2 (2.2%) 2 (2.3%)
Prolonging hospitalization 1 (1.1%) 4 (4.5%)
Congenital anomaly 0 (0%) 0 (0%)
Other 0 (0%) 2 (2.3%)
Severe adverse events 3 (3.3%) 3 (3.4%)
Drug-related adverse events
(investigator evaluation)
3 (3.3%) 6 (6.8%)
Patients with wound
hemorrhages
0 (0%) 1 (1.1%)
Leading to treatment
discontinuation
3 (3.3%) 3 (3.4%)
ALT: > 3  ULN anytime
postbaseline
1/90 (1.1%) 3/86 (3.5%)
Total bilirubin: > 1.5  ULN
anytime postbaseline
0/90 (0%) 2/86 (2.3%)
ALT Z alanine transaminase; ULN Z upper limit of the normal
range.
a Data expressed as number of patients (percentage).
Please cite this article in press as: Malhotra R, et al., Thromboprophyla
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However, subcutaneous administration of LMWHs such as
enoxaparin for up to 35 days could cause discomfort and
also makes it difficult for patients to adhere to treatment
postdischarge. A phase III trial (RE-NOVATE)8 demonstrated
that treatment with oral dabigatran 150 mg or 220 mg for
28e35 days was non inferior to subcutaneous enoxaparin
40 mg daily for the prevention of VTE and all-cause mor-
tality after THA. Recently, switch-therapy modalities have
been shown to provide clinicians an advantage of using
enoxaparin safely during the hospitalization period and
then switch to dabigatran for ease of administration during
the outpatient period.15
Eriksson et al9 have published the results of the efficacy
and safety of oral dabigatran versus subcutaneous enox-
aparin for thromboprophylaxis after primary THA in a
diverse global population (RE-NOVATE II). As a part of this
global study, 9% of total patients were enrolled in India.
The mean age of Indian patients was lower than the mean
age of the global population. The majority of the Indian
patients were men (62.6%), whereas patients of both the
sex equally participated in the global study. The mean body
mass index of the Indian population was lower
(23.6  4.6 kg/m2) compared with that of the global pop-
ulation (27.8  4.8 kg/m2). Surgical procedures mostly
involved the use of regional anesthesia in both the Indian
and global patients. The first dose of enoxaparin was
administered presurgery (median 12.6 hours) and dabiga-
tran was administered postsurgery (median 2.8 hours) in all
the Indian patients, whereas in the global counterpart,
enoxaparin and dabigatran were administered preopera-
tively as well as postoperatively depending on the local
practice followed in that particular country and/or as per
the investigator’s judgment.
In the Indian population, the primary outcome (total VTE
and all-cause mortality) occurred in 18.7% of patients in the
dabigatran group and 13.7% of patients in the enoxaparin
group [odds ratio for dabigatran over enoxaparin Z 1.4
(95% CI 0.6, 3.5)]. In the global population, primary
outcome occurred in 7.7% patients in the dabigatran group
and 8.8% patients in the enoxaparin group with an absolute
risk difference of 1.1% (95% CI, -3.8% to 1.6%). Dabigatran
was found to be noninferior to enoxaparin (p < 0.0001) in
RE-NOVATE II study. These observations are in line with the
earlier RE-NOVATE study.10 Furthermore, meta-analysis by
Gomez-Outes et al16 reported risk of symptomatic VTE with
dabigatran (relative risk 0.71, CI 0.23 to 2.12) is similar and
comparable to enoxaparin. Dabigatran is noninferior to
warfarin for the prevention of recurrent and fatal VTE for
up to 6 months.17
A systematic review by Singh et al18 reported an overall
30-day mortality rate of 0.3% across all type of arthro-
plasties in 28 out of 80 studies. In our study, major VTE and
VTE-related mortality were low in both the arms (7.9%
dabigatran and 9.9% enoxaparin) in Indian patients. Fewer
patients were diagnosed with proximal DVT in the dabiga-
tran group (7.9% India and 2.1% global population)
compared with the enoxaparin group (9.9% India and 3.9%
global population). However, in the Indian patients, distal
DVTs were more often reported in the dabigatran group
(10.7%) compared with the enoxaparin group (2.7%);
whereas in the global population 5.4% and 4.5% of thexis with dabigatran after total hip arthroplasty in Indian patients:
ATE II study, Asian Journal of Surgery (2015), http://dx.doi.org/
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groups respectively.
Distal DVTs (associated with calf veins) are less serious
than the proximal DVTs as thrombi in calf veins are gener-
ally small and have little chance of embolization. Distal
DVTs are therefore not usually associated with clinical
disability or other complications. Distal DVTs may be at risk
of embolization if they extend proximally.19 PE occurs
frequently in Indian patients with symptomatic DVT.20 In a
prospective study conducted in New Delhi, the overall
incidence of VTE was reported to be 6.12% and that of PE
was 0.6% among patients undergoing major orthopedic
surgeries (THA, TKA, and proximal femur fracture fixa-
tion).21 However, our study did not report any incidence of
PE in the Indian subpopulation, while three cases were
reported in the global population.
Anticoagulants prevent VTE or PE after THA/TKA;
nonetheless, risk of bleeding associated with their use can
be fatal. The risk of gastrointestinal bleeding related to
dabigatran is similar to warfarin.22 Also, dabigatran and
enoxaparin pose a similar risk of clinically significant
bleeding, major bleeding, and clinically relevant
nonmajor bleeding.16 Assessed using the same bleeding
criteria, the incidence of major bleeding events for dabi-
gatran 220 mg was comparatively lower in the Indian
population (1.1%) compared with the global population in
RE-NOVATE II and RE-NOVATE (1.4% and 2.0%) studies. Only
one patient had a major bleeding event prior to the
administration of dabigatran as evidenced by a fall in
hemoglobin level (>20 g/L) leading to blood transfusion
(2 units).
The occurrence of all AEs in the Indian population was
slightly lower (58.2% dabigatran group and 61.4% enox-
aparin group) than the global population (67% dabigatran
group and 69% enoxaparin group). Occurrence of SAEs was
more frequent in the enoxaparin (9.1%) group compared
with the dabigatran (4.4%) group in the Indian patients. As
per the investigator’s evaluation, a higher number of drug-
related AEs were reported in the enoxaparin group (6.8%)
than the dabigatran group (3.3%) in the Indian patients,
whereas in the global population, drug-related AEs were
similar in both the groups. Negligible risk of hepatic
dysfunction with dabigatran was observed in previously
reported phase III hip and knee arthroplasty studies, as well
as other studies in which dabigatran was administered for
up to 18 months. The current Indian data, as well as the
data in the previous studies do not report a clinically sig-
nificant difference in the safety profiles of dabigatran and
enoxaparin.8,10,11,23,24
The global results from the RE-NOVATE II study demon-
strate that dabigatran is an effective oral alternative to
enoxaparin for thromboprophylaxis. Analysis of data in a
limited group of Indian patients treated for the prevention
of VTE after THA indicate comparable effects of dabigatran
etexilate regarding its major efficacy and safety outcomes.
However, the data need to be interpreted with caution due
to the limited number of Indian patients (n Z 179).
The sample size for the Indian population was not suf-
ficiently powered to compare the two drugs. Descriptive
statistics used in this study, however, helped us to under-
stand the general trends seen in the Indian population
compared with the global population.Please cite this article in press as: Malhotra R, et al., Thromboprophyl
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10.1016/j.asjsur.2015.10.007Dabigatran offers an effective oral alternative to exist-
ing thromboprophylactic agents in patients undergoing
major orthopedic surgery.7 Oral administration enables
ease of use while drugedrug/foodedrug interactions
require dose adjustment. This adds to the practical
advantage of oral dabigatran over the vitamin K antagonists
and injectable heparins, which are inconvenient for
administration posthospital discharge, especially in a clin-
ical situation where an extended thromboprophylaxis is
required.
Financial disclosure
This study was sponsored by Boehringer Ingelheim India Pvt.
Ltd.
Acknowledgments
The authors thank the members of the data and safety
monitoring board, the investigators, study coordinators,
and radiologists who participated in this study.
References
1. Ethgen O, Bruyere O, Richy F, Dardennes C, Reginster JY.
Health-related quality of life in total hip and total knee
arthroplasty. A qualitative and systematic review of the liter-
ature. J Bone Joint Surg Am. 2004;86:963e974.
2. Seyler TM, Cui Q, Mihalko WM, Mont MA, Saleh KJ. Advances in
hip arthroplasty in the treatment of osteonecrosis. Instr Course
Lect. 2007;56:221e233.
3. Bullingam A, Strunin L. Prevention of postoperative venous
thromboembolism. Brit J Anaesth. 1995;75:622e630.
4. Jain V, Dhaon BK, Jaiswal A, Nigam V, Singla J. Deep vein
thrombosis after total hip and knee arthroplasty in Indian pa-
tients. Postgrad Med J. 2004;80:729e731.
5. Piovella F, Wang CJ, Lu H, et al. Deep-vein thrombosis rates
after major orthopedic surgery in Asia. An epidemiological
study based on postoperative screening with centrally adjudi-
cated bilateral venography. J Thromb Haemost. 2005;3:
2664e2670.
6. Perka C. Preoperative versus postoperative initiation of
thromboprophylaxis following major orthopedic surgery: safety
and efficacy of postoperative administration supported by
recent trials of new oral anticoagulants. Thromb J. 2011;9:17.
7. Kendoff D, Perka C, Fritsche HM, Gehrke T, Hube R. Oral
thromboprophylaxis following total hip or knee replacement:
review and multicenter experience with dabigatran etexilate.
Open Orthop J. 2011;5:395e399.
8. Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran
etexilate vs. subcutaneous enoxaparin for the prevention of
venous thromboembolism after total knee replacement: the
RE-MODEL randomized trial. J Thromb Haemost. 2007;5:
2178e2185.
9. Eriksson BI, Dahl OE, Huo MH, et al. Oral dabigatran versus
enoxaparin for thromboprophylaxis after primary total hip
arthroplasty (RE-NOVATE II*). A randomized, double-blind,
non-inferiority trial. Thromb Haemost. 2011;105:721e729.
10. Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate
versus enoxaparin for prevention of venous thromboembolism
after total hip replacement: a randomized, double-blind, non-
inferiority trial. Lancet. 2007;370:949e956.
11. RE-MOBILIZE Writing Committee, Ginsberg JS, Davidson BL,
et al. Oral thrombin inhibitor dabigatran etexilate vs Northaxis with dabigatran after total hip arthroplasty in Indian patients:
ATE II study, Asian Journal of Surgery (2015), http://dx.doi.org/
Thromboprophylaxis with dabigatran 7
+ MODELAmerican enoxaparin regimen for prevention of venous
thromboembolism after knee arthroplasty surgery. J Arthro-
plasty. 2009;24:1e9.
12. White RH, Henderson MC. Risk factors for venous thrombo-
embolism after total hip and knee replacement surgery. Curr
Opin Pulm Med. 2002;8:365e371.
13. Arcelus JI, Kudrna JC, Caprini JA. Venous thromboembolism
following major orthopedic surgery: what is the risk after
discharge? Orthopedics. 2006;29:506e516.
14. Nair V, Kumar R, Singh BK, Sharma A, Joshi GR, Pathak K.
Comparative study of extended versus short term thrombo-
prophylaxis in patients undergoing elective total hip and knee
arthroplasty in Indian population. Indian J Orthop. 2013;47:
161e167.
15. O¨zler T, Uluc¸ay C¸, O¨nal A, Altıntas‚ F. Comparison of switch-
therapy modalities (enoxaparin to rivaroxaban/dabigatran)
and enoxaparin monotherapy after hip and knee replacement.
Acta Orthop Traumatol Turc. 2015;49:255e259.
16. Go´mez-Outes A, Terleira-Ferna´ndez AI, Sua´rez-Gea ML, Vargas-
Castrillo´n E. Dabigatran, rivaroxaban, or apixaban versus
enoxaparin for thromboprophylaxis after total hip or knee
replacement: systematic review, meta-analysis, and indirect
treatment comparisons. BMJ. 2012;344:e3675.
17. Schulman S, Kakkar AK, Goldhaber SZ, et al. Treatment of
acute venous thromboembolism with dabigatran or warfarin
and pooled analysis. Circulation. 2014;129:764e772.Please cite this article in press as: Malhotra R, et al., Thromboprophyla
A subanalysis of a double-blind, double-dummy, randomized RE-NOV
10.1016/j.asjsur.2015.10.00718. Singh JA, Kundukulam J, Riddle DL, Strand V, Tugwell P. Early
postoperative mortality following joint arthroplasty: a sys-
tematic review. J Rheumatol. 2011;38:1507e1513.
19. Kearon C. Natural history of venous thromboembolism. Circu-
lation. 2003;107:I22eI30.
20. Parakh R, Kapadia SR, Sen I, Agarwal S, Grover T, Yadav A.
Pulmonary embolism: a frequent occurrence in Indian patients
with symptomatic lower limb venous thrombosis. Asian J Surg.
2006;29:86e91.
21. Bagaria V, Modi N, Panghate A, et al. Incidence and risk factors
for development of venous thromboembolism in Indian pa-
tients undergoing major orthopedic surgery: results of a pro-
spective study. Postgrad Med J. 2006;82:136e139.
22. Abraham NS, Singh S, Alexander GC, et al. Comparative risk of
gastrointestinal bleeding with dabigatran, rivaroxaban, and
warfarin: population based cohort study. BMJ. 2015;350:
h1857.
23. Connolly SJ, Ezekowitz MD, Yusuf S, et al, RE-LY Steering
Committee and Investigators. Dabigatran versus warfarin in
patients with atrial fibrillation. N Engl J Med. 2009;361:
1139e1151.
24. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus
warfarin in the treatment of acute venous thromboembolism.
N Engl J Med. 2009;361:2342e2352.xis with dabigatran after total hip arthroplasty in Indian patients:
ATE II study, Asian Journal of Surgery (2015), http://dx.doi.org/
